Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 1.00 |
| ▸ | MMP3 | P08254 | 17/20 | 1.00 |
| ▸ | MMP1 | P03956 | 17/20 | 1.00 |
| ▸ | MMP7 | P09237 | 15/20 | 1.00 |
| ▸ | MMP8 | P22894 | 2/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 2/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
| ▸ | FCER2 | P06734 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13253247 | 1.00 | MMP2 (1.00) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL13274148 | 1.00 | MMP2 (1.00) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4424468 | 0.91 | MMP2 (0.86) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4428170 | 0.88 | MMP2 (0.81) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4431907 | 0.87 | MMP2 (0.78) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4425335 | 0.87 | MMP2 (0.78) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4421723 | 0.87 | MMP2 (0.78) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4431974 | 0.87 | MMP2 (0.78) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4423322 | 0.85 | MMP2 (0.75) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL14081295 | 0.85 | MMP2 (0.73) | MMP2MMP3MMP1MMP7MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226922-A1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2010-09-09 | — | — | US | claimed |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PHARMACIA CORPORATION | 2004-06-24 | — | — | US | claimed |
| EP-3964242-B1 | SURGICAL STAPLER WITH END EFFECTOR COATING | CILAG GMBH INT (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20250329438-A1 | METHOD AND SYSTEM FOR TRANSITIONING HEALTH CARE BASED ON ANALYTICS | CAMICIA MICHELLE (US) | 2025-10-23 | — | — | US | disclosed |
| US-12447321-B2 | Medicant eluting adjuncts and methods of using medicant eluting adjuncts | CILAG GMBH INTERNATIONAL (CH) | 2025-10-21 | — | — | US | disclosed |
| EP-4132379-B1 | TISSUE THICKNESS COMPENSATING ADJUNCTS HAVING REGIONS OF DIFFERENTIAL EXPANSION | CILAG GMBH INT (CH) | 2025-05-07 | — | — | EP | disclosed |
| US-20250090586-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2025-03-20 | — | — | US | disclosed |
| EP-4161405-B1 | COMPRESSIBLE ADJUNCTS WITH DRUG RELEASE FEATURES | CILAG GMBH INT (CH) | 2024-12-18 | — | — | EP | disclosed |
| EP-4473916-A2 | COMPRESSIBLE ADJUNCTS DIFFERENT BEHAVIORAL ZONES | Cilag GmbH International (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-4146091-B1 | COMPRESSIBLE ADJUNCTS WITH FLUID CONTROL FEATURES | CILAG GMBH INT (CH) | 2024-12-04 | — | — | EP | disclosed |
| EP-4132380-B1 | COMPOSITE ADJUNCTS THAT DEGRADE THROUGH MULTIPLE DIFFERENT MECHANISMS | CILAG GMBH INT (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20220087677-A1 | SURGICAL ADJUNCTS WITH MEDICANTS AFFECTED BY ACTIVATORS | CILAG GMBH INTERNATIONAL (CH) | 2022-03-24 | — | — | US | disclosed |
| EP-3964242-A1 | SURGICAL STAPLER WITH END EFFECTOR COATING | Cilag GmbH International (CH) | 2022-03-09 | — | — | EP | disclosed |
| EP-2295088-B1 | Improved bone graft | WARSAW ORTHOPEDIC INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2012-05-31 | — | — | US | disclosed |
| EP-2041181-B1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MUENCHEN (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011011181-A1 | PHARMACOLOGICAL CHAPERONES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100226922-A1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2010-09-09 | — | — | US | disclosed |
| US-7413727-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2008-08-19 | — | — | US | disclosed |
| EP-1865001-A1 | Specific protease inhibitors and their use in cancer therapy | GSF-FORSCHUNGSZENTRUM FÜR UMWELT UND GESUNDHEIT, GMBH (DE) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | MMP8, MMP1, TIMP3 | MMP2 5/4885MMP3 11/4885MMP1 2/4885 |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PTGES2, PTGS2, PTGIS | MMP2 60/4885MMP3 39/4885MMP1 67/4885 |
| US-20250090586-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | THPO, PDGFRA, PDGFRB | MMP2 3559/4885MMP3 2499/4885MMP1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.